Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: May 13, 2025
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated May 13, 2025. The document serves to update investors and is incorporated into the company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The provided filing text is a cover sheet and does not contain specific financial data. The following metrics are not disclosed in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes regarding financial performance or operations are detailed in the provided text. The filing references a press release (Exhibit 99.1) which likely contains the substantive news, but the content of that release is not included in the input.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It notes the exclusion of a quotation from Jonathan Dickinson, CEO, and references to a live webcast from the incorporation by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 13, 2025) for the specific announcement details omitted from this cover sheet.
- Verify the content of the live webcast referenced in the excluded portions of the press release.
- Check the Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031) registration statements to understand how this press release updates the company's public disclosures.
- Confirm the latest financial position in the most recent Form 20-F or quarterly report, as this 6-K does not contain financial statements.